P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845580.45096.48 |
| _version_ | 1797287936137363456 |
|---|---|
| author | C. Ryan D. Brander P. Barr S. Tyekucheva Y. Ren L. Hackett M. McDonough K. Pena Del Aguila M. McEwan M. Collins J. Abramson E. Jacobsen A. LaCasce D. Fisher J. Brown M. Davids |
| author_facet | C. Ryan D. Brander P. Barr S. Tyekucheva Y. Ren L. Hackett M. McDonough K. Pena Del Aguila M. McEwan M. Collins J. Abramson E. Jacobsen A. LaCasce D. Fisher J. Brown M. Davids |
| author_sort | C. Ryan |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:42:01Z |
| format | Article |
| id | doaj.art-eaacdaea09b74a9391c7c439a6f4ac66 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:42:01Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-eaacdaea09b74a9391c7c439a6f4ac662024-03-02T03:51:52ZengWileyHemaSphere2572-92412022-06-01657257310.1097/01.HS9.0000845580.45096.48202206003-00572P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)C. Ryan0D. Brander1P. Barr2S. Tyekucheva3Y. Ren4L. Hackett5M. McDonough6K. Pena Del Aguila7M. McEwan8M. Collins9J. Abramson10E. Jacobsen11A. LaCasce12D. Fisher13J. Brown14M. Davids151 Medical Oncology, Dana-Farber Cancer Institute, Boston2 Duke University Cancer Center, Durham3 University of Rochester Wilmot Cancer Institute, Rochester4 Data Science, Dana-Farber Cancer Institute, Boston, United States of America4 Data Science, Dana-Farber Cancer Institute, Boston, United States of America1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Boston1 Medical Oncology, Dana-Farber Cancer Institute, Bostonhttp://journals.lww.com/10.1097/01.HS9.0000845580.45096.48 |
| spellingShingle | C. Ryan D. Brander P. Barr S. Tyekucheva Y. Ren L. Hackett M. McDonough K. Pena Del Aguila M. McEwan M. Collins J. Abramson E. Jacobsen A. LaCasce D. Fisher J. Brown M. Davids P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) HemaSphere |
| title | P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_full | P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_fullStr | P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_full_unstemmed | P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_short | P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_sort | p674 updated results of a phase 1b study of ibrutinib ibr plus obinutuzumab obin in patients with relapsed or refractory r r chronic lymphocytic leukemia cll |
| url | http://journals.lww.com/10.1097/01.HS9.0000845580.45096.48 |
| work_keys_str_mv | AT cryan p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT dbrander p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT pbarr p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT styekucheva p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT yren p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT lhackett p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT mmcdonough p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT kpenadelaguila p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT mmcewan p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT mcollins p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT jabramson p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT ejacobsen p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT alacasce p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT dfisher p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT jbrown p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll AT mdavids p674updatedresultsofaphase1bstudyofibrutinibibrplusobinutuzumabobininpatientswithrelapsedorrefractoryrrchroniclymphocyticleukemiacll |